HCM (HUTCHMED (China) Limited) Stock Financials & Earnings | Market Cap Arena

HCM (HUTCHMED (China) Limited) Stock Financials & Earnings | Market Cap Arena

HCMHUTCHMED (China) Limited

Mkt Cap$3B

Healthcare·Drug Manufacturers - Specialty & Generic·🇭🇰 Hong Kong·NASDAQ

Revenue (TTM)$602M

Net Income (TTM)$467M

EPS (TTM)$2.65

Free Cash Flow (TTM)-$50M

Gross Margin8.9%

Op. Margin-3.3%

Net Margin77.5%

FCF Margin-8.2%

P/S Ratio (TTM)4.2x

P/E Ratio (TTM)5.4x

YoY Rev Growth-1.4%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q3 22	$112M	-$77M	-$105M
Q4 22	$112M	-$77M	-$105M
Q1 23	$266M	$162M	$56M
Q2 23	$266M	$162M	$56M
Q3 23	$153M	-$14M	-$47M
Q4 23	$153M	-$14M	-$47M
Q1 24	$153M	$63M	-$14M
Q2 24	$153M	$63M	-$14M
Q3 24	$162M	-$28M	-$8M
Q4 24	$162M	-$28M	-$8M
Q1 25	$139M	$55M	-$2M
Q2 25	$139M	$55M	-$2M

Valuation

Quarter	P/S	P/E
Q3 22	4.6x	—
Q4 22	4.8x	—
Q1 23	3.6x	—
Q2 23	3.3x	—
Q3 23	3.2x	70.7x
Q4 23	3.0x	25.0x
Q1 24	3.5x	85.7x
Q2 24	4.1x	—
Q3 24	4.1x	—
Q4 24	4.0x	66.8x
Q1 25	4.1x	10.0x
Q2 25	4.2x	5.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$89M	-$100M
Q4 22	-$89M	-$100M
Q1 23	$113M	$101M
Q2 23	$113M	$101M
Q3 23	-$4M	-$8M
Q4 23	-$4M	-$8M
Q1 24	-$20M	-$25M
Q2 24	-$20M	-$25M
Q3 24	$20M	$16M
Q4 24	$20M	$16M
Q1 25	-$36M	-$41M
Q2 25	-$36M	-$41M

Capital Expenditures

CapEx

Quarter	CapEx
Q3 22	$10M
Q4 22	$10M
Q1 23	$12M
Q2 23	$12M
Q3 23	$4M
Q4 23	$4M
Q1 24	$5M
Q2 24	$5M
Q3 24	$4M
Q4 24	$4M
Q1 25	$5M
Q2 25	$5M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	+12.9%	+13.6%
Q4 22	-18.8%	+435.8%
Q1 23	+163.7%	+5.6%
Q2 23	+31.9%	-47.2%
Q3 23	+36.0%	-8.5%
Q4 23	+36.0%	-8.5%
Q1 24	-42.6%	-20.9%
Q2 24	-42.6%	-20.9%
Q3 24	+6.4%	-14.5%
Q4 24	+6.4%	-14.5%
Q1 25	-9.2%	-15.6%
Q2 25	-9.2%	-15.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$8M	6.8%
Q4 22	$8M	6.8%
Q1 23	$7M	2.6%
Q2 23	$7M	2.6%
Q3 23	$11M	7.5%
Q4 23	$11M	7.5%
Q1 24	$6M	3.7%
Q2 24	$6M	3.7%
Q3 24	$5M	3.2%
Q4 24	$5M	3.2%
Q1 25	$4M	2.8%
Q2 25	$4M	2.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 22	$105M	$17M	$11M
Q4 22	$105M	$17M	$11M
Q1 23	$72M	$21M	$13M
Q2 23	$72M	$21M	$13M
Q3 23	$79M	$19M	$13M
Q4 23	$79M	$19M	$13M
Q1 24	$48M	$15M	$14M
Q2 24	$48M	$15M	$14M
Q3 24	$59M	$32M	$24M
Q4 24	$59M	$32M	$24M
Q1 25	$36M	$14M	$7M
Q2 25	$36M	$14M	$7M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$313M	$320M	$633M
Q4 22	$313M	$318M	$631M
Q1 23	$223M	$635M	$858M
Q2 23	$223M	$633M	$856M
Q3 23	$284M	$605M	$889M
Q4 23	$284M	$603M	$886M
Q1 24	$204M	$600M	$804M
Q2 24	$204M	$600M	$804M
Q3 24	$154M	$685M	$839M
Q4 24	$154M	$682M	$836M
Q1 25	$111M	$1.3B	$1.4B
Q2 25	$1.4B	$0	$1.4B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q3 22	169M	-0.5%
Q4 22	169M	+0.0%
Q1 23	173M	+2.6%
Q2 23	173M	+0.0%
Q3 23	170M	-1.7%
Q4 23	170M	+0.0%
Q1 24	175M	+2.4%
Q2 24	175M	+0.0%
Q3 24	175M	+0.1%
Q4 24	175M	+0.0%
Q1 25	175M	-0.1%
Q2 25	175M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 13	—	—
FY 14	—	—
FY 15	—	—
FY 16	$366K	590
FY 17	$428K	563
FY 18	$300K	714
FY 19	$240K	853
FY 20	$178K	1K
FY 21	$124K	3K
FY 22	$211K	2K
FY 23	$422K	2K
FY 24	$348K	2K